tenosynovial giant cell tumor
Jump to navigation
Jump to search
Epidemiology
- rare
- more common in women than men
- young to middle-aged adults
Pathology
- benign neoplasm
- abnormal proliferation of giant cells
Clinical manifestations
- arthritis
- joint pain, especially during joint movement
- joint swelling and stiffness
- joint instability
- warmth & erythema over the affected joint
- may be confined to a single joint or involve multiple joints
- most common in hands, knees & hip
Laboratory
- tumor biopsy
Management
- surgery (1st line)
- radiation therapy
- imatinib
- tofacitinib
- pexidartinib (Turalio) FDA approved (2019)
- vimseltinib (Romvimza) FDA approved (2025)
More general terms
References
- ↑ Verspoor FGM, Hannink G. Systemic treatment of tenosynovial giant cell tumours in context. Lancet. 2019 Aug 10;394(10197):446-448. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31229239
- ↑ Gounder MM, Thomas DM, Tap WD. Locally Aggressive Connective Tissue Tumors. J Clin Oncol. 2018 Jan 10;36(2):202-209. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29220303
- ↑ Peyraud F, Cousin S, Italiano A. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19(11):70. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28875266
- ↑ Cannarile MA, Weisser M, Jacob W et al Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017 Jul 18;5(1):53. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28716061 Free PMC Article